All Stories

  1. Solid Organ Transplantation
  2. What happens if you smoke after receiving a kidney transplant?
  3. Wisely Choosing: Aging, Precision, and Medicine
  4. Is Skipping Breakfast a Marker for Current Smoking?
  5. Anti-rejection and immune therapy are associated with risk of death from infection and malignancy
  6. Flosequinan
  7. Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results
  8. Diabetes in the Older Patient: A Role for C-Peptide?
  9. Use of Calcium Channel Blockers After Heart Transplantation
  10. Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial
  11. Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions
  12. Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines
  13. Metformin-SGLT2, Dehydration, and Acidosis Potential
  14. The Fight Against Multidrug-Resistant Bacteria
  15. Does calcium channel blockade have a role in prevention of expression of sepsis in renal transplant recipients?
  16. Diabetic microvascular triopathy, smoking, and risk of cardiovascular events
  17. Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review
  18. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus
  19. Cardiovascular Risk Reduction and the Community Pharmacist ∗
  20. Response to Panagiotis
  21. Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients
  22. Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study)
  23. Screening for Type 2 Diabetes Mellitus
  24. Getting Lost Among the Guidelines: The Difference Between Patient-focused Treatment and Population Management
  25. Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial
  26. Letter by Weinrauch and Barkoudah Regarding Article, "Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Results From the Outcomes Registry for Better Informed Treatment of Atrial ...
  27. Resistant Hypertension in Diabetes Mellitus
  28. Sudden Death in Adolescent Athletes
  29. Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia
  30. Surgery vs Watchful Waiting for Mitral Regurgitation
  31. The autonomic nervous system and renal physiology
  32. Risk Stratification of Resistant Hypertension in Chronic Kidney Disease ∗
  33. Ultrafiltration in End-Stage Heart Failure
  34. Pathophysiology of Obesity-Related Renal Dysfunction Contributes to Diabetic Nephropathy
  35. Stroke Center Designation and Mortality
  36. Diabetic microvascular complications: possible targets for improved macrovascular outcomes
  37. Disruption of Coronary Vasomotor Function: The Coronary Spasm Syndrome
  38. Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus
  39. What have trials of pulsatile intravenous insulin taught us?
  40. Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney
  41. Aiming for the Best Control of Glycemia in Patients With Heart Failure and Type 2 Diabetes
  42. A pilot study to assess utility of changes in elements of the Diabetes Impact Management Scale in evaluating diabetic patients for progressive nephropathy
  43. Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit
  44. Mapping Directions for the Cardiorenal Conundrum
  45. A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria
  46. How Can the Care of Diabetic ESRD Patients Be Improved?
  47. Regression of Left Ventricular Hypertrophy in Diabetic Nephropathy: Loss of Parasympathetic Function Predicts Response to Treatment
  48. Risk factors for thromboembolic events in renal failure
  49. Left Ventricular Mass Reduction in Type 1 Diabetic Patients With Nephropathy
  50. Renal artery stenosis: “fortuitous diagnosis,” problematic therapy**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of C...
  51. 1145-120 Left ventricular mass reduction in type 1 diabetes mellitus
  52. Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus
  53. Marked abnormalities in heart rate variability are associated with progressive deterioration of renal function in type I diabetic patients with overt nephropathy
  54. Hypertensive control in hemodialysis units
  55. Early thromboembolic events in female dialysis patients with diabetes mellitus
  56. Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus
  57. Fibrinogen and Factor VII Levels Improve With Glycemic Control in Patients With Type 1 Diabetes Mellitus Who Have Microvascular Complications
  58. Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy
  59. Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease
  60. Prospective evaluation of autonomic dysfunction in aggressive management of diabetic microangiopathy
  61. Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy
  62. Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy
  63. A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation
  64. Relation of Heart Rate Variability and Serum Lipoproteins in Type 1 Diabetes Mellitus and Chronic Stable Angina Pectoris
  65. Short- and Long-Term Reproducibility of Heart Rate Variability in Patients With Long-Standing Type I Diabetes Mellitus
  66. Relationship Between Autonomic Function and Plasma Fibrinogen, Viscosity, and Elements of Fibrinolytic Activity in Diabetic Nephropathy
  67. Ethics and Organ Use
  68. Ethics and organ use
  69. Autonomic function in type I diabetes mellitus complicated by nephropathy a cross-sectional analysis in the presymptomatic phase
  70. Preliminary Screening of the Relationship of Serum Lipids to Survival of Chronic Dialysis Patients
  71. Ventricular arrhythmia and long-term survival with maintenance dialysis
  72. Usefulness of left ventricular size and function in predicting survival in chronic dialysis patients with diabetes mellitus
  73. Preoperative evaluation for diabetic renal transplantation: Impact of clinical, laboratory, and echocardiographic parameters on patient and allograft survival
  74. Increased Infection Rate in Diabetic Dialysis Patients Exposed to Cocaine
  75. Platelet hyperreactivity in diabetics: Relation to time of onset of acute myocardial infarction
  76. Cardiac Conduction Defects Associated with Aortic and Mitral Valve Calcification in Dialysis Patients
  77. Amyloid Deposition in Serosal Membranes-Reply
  78. Decreased serum lithium during verapamil therapy
  79. Amyloid Deposition in Serosal Membranes
  80. Amyloid deposition in serosal membranes. Its occurrence with cardiac tamponade, bilateral ureteral obstruction, and gastrointestinal bleeding
  81. Cardiorenal Failure: Treatment of Refractory Biventricular Failure by Peritoneal Dialysis
  82. Insulin Resistance With Pancreatic Pseudocyst Relieved by Percutaneous Drainage
  83. Insulin resistance with pancreatic pseudocyst relieved by percutaneous drainage
  84. Elimination of Requirement for Exogenous Insulin Therapy in Diabetic Renal Failure
  85. Myocardial dysfunction without coronary artery disease in diabetic renal failure
  86. Diagnosis of Neuropathic vs Myopathic Disease-Reply
  87. Contrast Media-Induced Acute Renal Failure
  88. Contrast media-induced acute renal failure. Use of creatinine clearance to determine risk in elderly diabetic patients
  89. Decreased Insulin Requirement in Acute Renal Failure in Diabetic Nephropathy
  90. Decreased insulin requirement in acute renal failure in diabetic nephropathy
  91. Mitral Valve Prolapse in Rheumatic Mitral Stenosis
  92. Provocative testing for coronary arterial spasm: Rationale, risk and clinical illustrations
  93. Coronary Angiography and Acute Renal Failure in Diabetic Azotemic Nephropathy
  94. Acute renal failure after cerebral arteriography in a diabetic patient
  95. Generic drugs does not guarantee cost reduction for the patient